Analysis Tools
mortality/aging
|
• homozygous embryos exhibit complete lethality by E10.5
|
growth/size/body
|
• at E8.5-E9.5, homozygous embryos are developmentally delayed and exhibit a smaller body size than wild-type embryos
|
|
• at E8.5, homozygous embryos are smaller than heterozygous and wild-type embryos
|
embryo
|
• homozygous embryos show severe defects in early embryonic development, including impaired neuroectoderm differentiation
|
|
• at E8.5-E9.5, homozygous embryos are developmentally delayed and exhibit a smaller body size than wild-type embryos
|
|
• morphological defects are already detectable at E8.5
|
|
• at E8.5, homozygous embryos are smaller than heterozygous and wild-type embryos
|
|
• at E9.5, homozygous embryos show a ~50% reduction in the proportion of neuroectoderm cells, whereas almost all remaining cell types remain unaffected, suggesting a defect in neuroectoderm cell development and/or maintenance
|
|
• at E8.5-E9.5, neural folds in the cephalic region are only just beginning to fuse along the specific closure sites, resembling the morphology of earlier (E8) stages
|
nervous system
|
• at E9.5, homozygous embryos show a ~50% reduction in the proportion of neuroectoderm cells, whereas almost all remaining cell types remain unaffected, suggesting a defect in neuroectoderm cell development and/or maintenance
|
|
• at E8.5-E9.5, neural folds in the cephalic region are only just beginning to fuse along the specific closure sites, resembling the morphology of earlier (E8) stages
|
cardiovascular system
|
• at E9.5, homozygous embryos show an increase in the proportion of heart field cells
|
